I don't see 'em!

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 5, 1997, Pages 302-307

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038787518     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Preskorn S, Lacey R. Polypharmacy. When is it rational? J Pract Psychiatry Behav Health 1995;1:92-8.
2. Preskorn S. What is the message in the alphabet soup of cytochrome P450 enzymes? J Pract Psychiatry Behav Health 1995;1: 237-40.
3. Preskorn S. Let the data speak to you. J Pract Psychiatry Behav Health 1997;3: 45-8.
4. Preskorn S. Do you believe in magic? J Pract Psychiatry Behav Health 1997;3:99-103.
5. Preskorn S; Freeny P, eds. Clinical pharmacology of selective serotonin reuptake inhibitors. 1st ed. Caddo, OK: Professional Communications; 1996.
6. Shad MU, Carmichael CA, Preskorn S, Horst WD. Prevalence of polypharmacy in different clinical settings and its relation to drug-drug interactions. Presented at the annual American Psychiatric Association meeting, San Diego, CA, May 17-22, 1997.
7. Young C. A case of neuroleptic malignant syndrome and serotonin disturbance (letter to the editor). J Clin Psychopharmacol 1997;17(1):65-6.
8. Janicak P, Davis J, Preskorn S, Ayd FJ, Jr, Retford D, eds. Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins; 1993.
9. Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990;253: 803-11.
10. Curzon G, Kennett GA. mCPP: a tool for studying behavioral responses associated with 5-HT1c receptors. Trends Pharmacol Sci 1990;11:181-2.
11. Kennett GA, Wood MD, Glen A, et al. In vivo properties of SB 2000646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 1994; 111:797-802.
12. Preskorn S. Why did Terry fall off the dose-response curve? J Pract Psychiatry Behav Health 1996;2:39-43.
13. Harvey A, Preskorn S. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors Part I. J Clin Psychopharmacol 1996;16(4): 273-85
14. and Harvey A, Preskorn S. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors Part II. J Clin Psychopharmacol Part II 16(5):345-55.
15. Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996;42:573-81.
16. Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
17. Preskorn S. Have you phenotyped your patient lately? J Pract Psychiatry Behav Health 1996;2(2):115-7.
18. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7:193-202.
19. Dayer P, Leemann T, Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 1989;45:34-40.
20. Brosen K, Hansen JG, Neilsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
21. Ereshefsky, L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(3) (Suppl 2):37-50.
22. Otton SV, Wu D, Joffe RT, Cheung SW, Selleers EM. Inhibition by fluoxetine of cytochrome P450 2 D6 activity. Clin Pharmacol Ther 1993;53:401-9.
23. Frisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 1994; 271:83-90.
24. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989;80(Suppl 350):60-75.
25. Alderman J, Preskorn S, Greenblatt D, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-91.
26. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978;179: 641-68.
27. Mori S, Matsuura T, Takino T, Sano Y. Light and electron microscopic immunohistochemical studies of serotonin nerve fibres in the substantia nigra of the rat, cat and monkey. Anat Embryol 1987;176:13-8.
28. Phillipson OT. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J Comp Neurol 1979;187: 117-44.
29. Steinbusch HWM; Björklund A, Hökfelt T, Kuhar MJ, eds. Handbook of Chemical Neuroanatomy. Amsterdam: Elsevier, 1984; Serotonin-immunoreactive neurons and their projections in the CNS. Classical transmitters and transmitter receptors in the CNS. Part II. p. 68-125.
30. Prisco S, Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Brit J Pharm 1995;116: 1923-31.
31. DeMontigny C, Cournoyer G, Morissette R, Langlois R, Caille G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-34.
32. Armstrong SC, Schweitzer SM. Delirium associated with paroxetine and benztropine combination. Am J Psychiatry 1997;154: 581-2.